Logo image of ACRX

ACELRX PHARMACEUTICALS INC (ACRX) Stock Fundamental Analysis

NASDAQ:ACRX - Nasdaq - US00444T2096 - Common Stock - Currency: USD

0.86  +0.06 (+7.5%)

After market: 0.8719 +0.01 (+1.38%)

Fundamental Rating

3

Overall ACRX gets a fundamental rating of 3 out of 10. We evaluated ACRX against 198 industry peers in the Pharmaceuticals industry. While ACRX seems to be doing ok healthwise, there are quite some concerns on its profitability. ACRX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ACRX has reported negative net income.
In the past year ACRX has reported a negative cash flow from operations.
In the past 5 years ACRX reported 4 times negative net income.
ACRX had a negative operating cash flow in each of the past 5 years.
ACRX Yearly Net Income VS EBIT VS OCF VS FCFACRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M

1.2 Ratios

ACRX's Return On Assets of -113.65% is on the low side compared to the rest of the industry. ACRX is outperformed by 84.31% of its industry peers.
ACRX has a worse Return On Equity (-144.70%) than 68.63% of its industry peers.
Industry RankSector Rank
ROA -113.65%
ROE -144.7%
ROIC N/A
ROA(3y)-5.62%
ROA(5y)-22.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACRX Yearly ROA, ROE, ROICACRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 -500 -1K

1.3 Margins

ACRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACRX Yearly Profit, Operating, Gross MarginsACRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 1K -1K 2K -2K

More info and screens

6

2. Health

2.1 Basic Checks

ACRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACRX has more shares outstanding
ACRX has a better debt/assets ratio than last year.
ACRX Yearly Shares OutstandingACRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M
ACRX Yearly Total Debt VS Total AssetsACRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -26.92, we must say that ACRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -26.92, ACRX is not doing good in the industry: 88.73% of the companies in the same industry are doing better.
There is no outstanding debt for ACRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.92
ROIC/WACCN/A
WACC9.57%
ACRX Yearly LT Debt VS Equity VS FCFACRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 4.00 indicates that ACRX has no problem at all paying its short term obligations.
ACRX has a Current ratio (4.00) which is in line with its industry peers.
ACRX has a Quick Ratio of 4.00. This indicates that ACRX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ACRX (4.00) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4
Quick Ratio 4
ACRX Yearly Current Assets VS Current LiabilitesACRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.88% over the past year.
ACRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -37.23%.
ACRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -26.04% yearly.
EPS 1Y (TTM)50.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.49%
Revenue 1Y (TTM)-37.23%
Revenue growth 3Y-8.23%
Revenue growth 5Y-26.04%
Sales Q2Q%N/A

3.2 Future

ACRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.09% yearly.
Based on estimates for the next years, ACRX will show a very strong growth in Revenue. The Revenue will grow by 36.49% on average per year.
EPS Next Y72.27%
EPS Next 2Y34.78%
EPS Next 3Y22.12%
EPS Next 5Y15.09%
Revenue Next Year-91.49%
Revenue Next 2Y-52.31%
Revenue Next 3Y-25.27%
Revenue Next 5Y36.49%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ACRX Yearly Revenue VS EstimatesACRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M
ACRX Yearly EPS VS EstimatesACRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 5 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACRX. In the last year negative earnings were reported.
Also next year ACRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRX Price Earnings VS Forward Price EarningsACRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRX Per share dataACRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ACRX's earnings are expected to grow with 22.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.78%
EPS Next 3Y22.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACELRX PHARMACEUTICALS INC

NASDAQ:ACRX (1/9/2024, 8:00:00 PM)

After market: 0.8719 +0.01 (+1.38%)

0.86

+0.06 (+7.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-08 2023-11-08/amc
Earnings (Next)03-28 2024-03-28/amc
Inst Owners22.97%
Inst Owner Change0%
Ins Owners3.13%
Ins Owner Change0%
Market Cap14.58M
Analysts82.5
Price Target4.72 (448.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49%
Min EPS beat(2)26.01%
Max EPS beat(2)71.99%
EPS beat(4)3
Avg EPS beat(4)13.22%
Min EPS beat(4)-92.23%
Max EPS beat(4)71.99%
EPS beat(8)7
Avg EPS beat(8)14.45%
EPS beat(12)10
Avg EPS beat(12)10.52%
EPS beat(16)12
Avg EPS beat(16)9.08%
Revenue beat(2)1
Avg Revenue beat(2)108.13%
Min Revenue beat(2)-10.53%
Max Revenue beat(2)226.8%
Revenue beat(4)1
Avg Revenue beat(4)5.43%
Min Revenue beat(4)-100%
Max Revenue beat(4)226.8%
Revenue beat(8)1
Avg Revenue beat(8)-47.29%
Revenue beat(12)1
Avg Revenue beat(12)-47.44%
Revenue beat(16)2
Avg Revenue beat(16)-44.57%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26%
EPS NY rev (1m)0%
EPS NY rev (3m)20.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.51
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 1.53
EV/EBITDA N/A
EPS(TTM)-2.23
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS0.04
BVpS1.08
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -113.65%
ROE -144.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-5.62%
ROA(5y)-22.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.54%
Cap/Sales 22.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4
Quick Ratio 4
Altman-Z -26.92
F-Score5
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)71.75%
Cap/Depr(5y)112.88%
Cap/Sales(3y)39.85%
Cap/Sales(5y)61.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.49%
EPS Next Y72.27%
EPS Next 2Y34.78%
EPS Next 3Y22.12%
EPS Next 5Y15.09%
Revenue 1Y (TTM)-37.23%
Revenue growth 3Y-8.23%
Revenue growth 5Y-26.04%
Sales Q2Q%N/A
Revenue Next Year-91.49%
Revenue Next 2Y-52.31%
Revenue Next 3Y-25.27%
Revenue Next 5Y36.49%
EBIT growth 1Y11.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.11%
OCF growth 3YN/A
OCF growth 5YN/A